Form 4: Fennec Pharmaceuticals CFO Robert Andrade Reports Share Release
SEC Form 4 Filing
Robert Andrade, CFO of Fennec Pharmaceuticals, reports the release of 1,042 common shares from restriction on March 31, 2025, resulting in a decrease in his beneficially owned securities.
Summary
- Robert Andrade, the Chief Financial Officer of Fennec Pharmaceuticals, filed a Form 4 on April 1, 2025.
- The report details a transaction that occurred on March 31, 2025, where 1,042 common shares were released from restriction.
- This release resulted in a decrease in Andrade's beneficially owned securities, leaving him with 132,591 shares.
Sentiment
Score: 5
Explanation: This is a routine regulatory filing related to share release, with no inherent positive or negative sentiment.
Industry Context
Form 4 filings are a routine part of compliance for company insiders and provide transparency into their transactions in the company's stock.
Stakeholder Impact
- The transaction may have a minor impact on shareholders due to the change in insider ownership.
Key Dates
| Date | Description |
|---|---|
| 03/31/2023 | Date shares were originally awarded. |
| 03/31/2025 | Date of the share release transaction. |
| 04/01/2025 | Date the Form 4 was filed. |
Keywords
Form 4, Beneficial Ownership, Robert Andrade, Fennec Pharmaceuticals, FENC, CFO, Common Shares, Share Release
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.